A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Triptorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms DIE-NIS
- Sponsors Ipsen
- 04 Feb 2022 Results published in the Medicine
- 30 Jul 2021 Results of post hoc analysis assessing symptom control between patients receiving 1 to 3 triptorelin injections and those receiving 4 to 6 injections within 24 months published in the Medicine
- 23 Aug 2018 Status changed from active, no longer recruiting to completed.